Forecast

There is no analyst data available for this company.

News Go to news feed

Integrated Diagnostics boosts 2025 revenue by 37% – shares barely react

Integrated Diagnostics reports a 37% revenue increase for 2025 to $2.07 billion and an adjusted net income of 1.26 billion EGP (+79%). Gross and EBITDA margins improved to 42.7% and 34.9%, respectively, while Egypt contributed 84.6% of revenue. The company plans around 200 new outlets in Egypt and Saudi Arabia and is focusing on higher-value diagnostics and digital integration. Geopolitical risks in the region weigh on investor sentiment; the stock rose only 0.32% after the results. » More on de.investing.com
Integrated Diagnostics reports 41% revenue growth, shares fall despite strong metrics

Integrated Diagnostics recorded 41% revenue growth in the first nine-month period of 2025, driven by a 10% higher test volume and a 28% higher average revenue per test. Gross margin rose to 43% and EBITDA margin to 35%, while adjusted net profit increased by 119%. The company opened 103 new branches in Egypt and plans expansion into Saudi Arabia with planned Capex of $20m (2026–2030). Despite the strong figures, the share price fell by 3.03%, indicating mixed investor sentiment or uncertainties about the future. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, INTERGRATED DIA.H DL 0,25 Aktie has already paid €0.00744 in dividends. The last payout was in June.

Fundamentals

Metric	Value
Market capitalization	€276.55M
Number of shares	581.33M
52-week high/low	€0.60 - €0.39
Dividend yield	1.58%
Dividends TTM	€0.00744
Beta	0.40
P/E ratio	11.57
PEG ratio	0.23
P/B ratio	3.91
P/S ratio	1.98

Company profile

Integrated Diagnostics Holdings plc, ein Unternehmen im Bereich der Gesundheitsfürsorge, bietet verschiedene medizinische Diagnostikdienste für Patienten an. Das Unternehmen bietet etwa 2.000 diagnostische Tests an, darunter Immunologie, Mikrobiologie, Hämatologie, Endokrinologie, klinische Chemie, Molekularbiologie, Zytogenetik, Histopathologie und Radiologie. Das Unternehmen ist in Ägypten, Jordanien, Sudan und Nigeria tätig. Zum 30. Dezember 2021 unterhielt es ein Netz von 452 Zweiglaboren. Das Unternehmen wurde 1979 gegründet und hat seinen Hauptsitz in Saint Helier, Jersey.